{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T16:00:40Z","timestamp":1792425640412,"version":"4.5.0"},"reference-count":32,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2018,7,13]],"date-time":"2018-07-13T00:00:00Z","timestamp":1531440000000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"DOI":"10.3389\/fneur.2018.00579","type":"journal-article","created":{"date-parts":[[2018,7,13]],"date-time":"2018-07-13T05:02:06Z","timestamp":1531458126000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":64,"title":["Clinical Management of Epilepsy With Glutamic Acid Decarboxylase Antibody Positivity: The Interplay Between Immunotherapy and Anti-epileptic Drugs"],"prefix":"10.3389","volume":"9","author":[{"given":"Kari-Matti","family":"M\u00e4kel\u00e4","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aki","family":"Hietaharju","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antti","family":"Brander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jukka","family":"Peltola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2018,7,13]]},"reference":[{"key":"B1","first-page":"57","article-title":"Innate and adaptive immunity in human epilepsies","volume-title":"Epilepsia","author":"Bauer","year":"2017"},{"key":"B2","first-page":"46","article-title":"Autoantibodies to glutamic acid decarboxylase in patients with therapy-resistant epilepsy","volume-title":"Neurology","author":"Peltola","year":"2000"},{"key":"B3","first-page":"15","article-title":"GAD65 neurological autoimmunity","volume-title":"Muscle Nerve","author":"McKeon","year":"2017"},{"key":"B4","first-page":"1622","article-title":"Immunopathology of autoantibody-associated encephalitides: clues for pathogenesis","volume-title":"Brain","author":"Bien","year":"2012"},{"key":"B5","first-page":"73","article-title":"GAD65 epitope mapping and search for novel autoantibodies in GAD-associated neurological disorders","volume-title":"J Neuroimmunol.","author":"Fouka","year":"2015"},{"key":"B6","first-page":"e122","article-title":"ILAE type 3 hippocampal sclerosis in patients with anti-GAD-related epilepsy","volume-title":"Neurol Neuroimmunol Neuroinflamm.","author":"Glover","year":"2015"},{"key":"B7","first-page":"475","article-title":"Distinct white matter integrity in glutamic acid decarboxylase and voltage-gated potassium channel-complex antibody-associated limbic encephalitis","volume-title":"Epilepsia","author":"Wagner","year":"2016"},{"key":"B8","first-page":"397","article-title":"Neurological autoantibody prevalence in epilepsy of unknown etiology","volume-title":"JAMA Neurol.","author":"Dubey","year":"2017"},{"key":"B9","first-page":"1028","article-title":"Prevalence of neurologic autoantibodies in cohorts of patients with new and established epilepsy","volume-title":"Epilepsia","author":"Brenner","year":"2013"},{"key":"B10","first-page":"827","article-title":"Prevalence and immunological spectrum of temporal lobe epilepsy with glutamic acid decarboxylase antibodies","volume-title":"Eur J Neurol.","author":"Falip","year":"2012"},{"key":"B11","first-page":"57","article-title":"Treatment of immune-mediated temporal lobe epilepsy with GAD antibodies","volume-title":"Seizure","author":"Malter","year":"2015"},{"key":"B12","first-page":"470","article-title":"Antibodies to glutamic acid decarboxylase define a form of limbic encephalitis","volume-title":"Ann Neurol.","author":"Malter","year":"2010"},{"key":"B13","first-page":"306","article-title":"Extralimbic autoimmune encephalitis associated with glutamic acid decarboxylase antibodies: an underdiagnosed entity?","volume-title":"Epilepsy Behav.","author":"Najjar","year":"2011"},{"key":"B14","first-page":"177","article-title":"Long latency between GAD-antibody detection and development of limbic encephalitis\u2013a case report","volume-title":"BMC Neurol.","author":"Fauser","year":"2015"},{"key":"B15","first-page":"331","article-title":"Antiglutamic acid decarboxylase 65 (GAD65) antibody-associated epilepsy","volume-title":"Epilepsy Behav","author":"Daif","year":"2018"},{"key":"B16","first-page":"34","article-title":"Refractory status epilepticus and glutamic acid decarboxylase antibodies in adults: presentation, treatment and outcomes","volume-title":"Epileptic Disord.","author":"Khawaja","year":"2016"},{"key":"B17","first-page":"345","article-title":"Seizures and risk of epilepsy in autoimmune and other inflammatory encephalitis","volume-title":"Curr Opin Neurol.","author":"Spatola","year":"2017"},{"key":"B18","first-page":"531","article-title":"Instruction manual for the ILAE 2017 operational classification of seizure types","volume-title":"Epilepsia","author":"Fisher","year":"2017"},{"key":"B19","first-page":"522","article-title":"Operational classification of seizure types by the International League Against Epilepsy: Position Paper of the ILAE Commission for Classification and Terminology","volume-title":"Epilepsia","author":"Fisher","year":"2017"},{"key":"B20","first-page":"1","article-title":"Immunological perspectives of temporal lobe seizures","volume-title":"J Neuroimmunol.","author":"Liimatainen","year":"2013"},{"key":"B21","first-page":"1932","article-title":"Inverse Relationship between organ-specific autoantibodies and systemic immune mediators in type 1 diabetes and type 2 diabetes: action LADA 11","volume-title":"Diabetes Care","author":"Schloot","year":"2016"},{"key":"B22","first-page":"760","article-title":"Clinical significance of glutamic acid decarboxylase antibodies in patients with epilepsy","volume-title":"Epilepsia","author":"Liimatainen","year":"2010"},{"key":"B23","first-page":"e000076","article-title":"Presence of anti-GAD in a non-diabetic population of adults; time dynamics and clinical influence: results from the HUNT study","volume-title":"BMJ Open Diabetes Res Care","author":"Sorgjerd","year":"2015"},{"key":"B24","first-page":"391","article-title":"A clinical approach to diagnosis of autoimmune encephalitis","volume-title":"Lancet Neurol.","author":"Graus","year":"2016"},{"key":"B25","first-page":"592","article-title":"Lack of antibodies to NMDAR or VGKC-complex in GAD and cardiolipin antibody-positive refractory epilepsy","volume-title":"Epilepsy Res.","author":"Liimatainen","year":"2014"},{"key":"B26","first-page":"18","article-title":"Seizure control and cognitive improvement via immunotherapy in late onset epilepsy patients with paraneoplastic versus GAD65 autoantibody-associated limbic encephalitis","volume-title":"Epilepsy Behav","author":"Hansen","year":"2016"},{"key":"B27","first-page":"229","article-title":"Plasma exchange for anti GAD associated non paraneoplastic limbic encephalitis","volume-title":"Transfus Apher Sci.","author":"Mazzi","year":"2008"},{"key":"B28","first-page":"167","article-title":"Treating a GAD65 antibody-associated limbic encephalitis with basiliximab: a case study","volume-title":"Front Neurol.","author":"Widman","year":"2015"},{"key":"B29","first-page":"557","article-title":"B cells as therapeutic targets in autoimmune neurological disorders","volume-title":"Nat Clin Pract Neurol.","author":"Dalakas","year":"2008"},{"key":"B30","doi-asserted-by":"crossref","DOI":"10.1007\/s13760-018-0880-5","article-title":"Autoimmune encephalitis associated with glutamic acid decarboxylase antibodies: a case series","volume-title":"Acta Neurol Belg.","author":"Incecik","year":"2018"},{"key":"B31","first-page":"92","article-title":"A case of immune-mediated encephalopathy showing refractory epilepsy and extensive brain MRI lesions associated with anti-glutamic acid decarboxylase antibody","volume-title":"Rinsho Shinkeigaku","author":"Kobayakawa","year":"2010"},{"key":"B32","first-page":"e353","article-title":"Antiepileptic drug therapy in patients with autoimmune epilepsy","volume-title":"Neurol Neuroimmunol Neuroinflamm.","author":"Feyissa","year":"2017"}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fneur.2018.00579\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,7,13]],"date-time":"2018-07-13T05:02:10Z","timestamp":1531458130000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fneur.2018.00579\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7,13]]},"references-count":32,"alternative-id":["10.3389\/fneur.2018.00579"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2018.00579","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,7,13]]},"article-number":"579"}}